RSS-Feed abonnieren
DOI: 10.1055/s-0034-1398552
Pasireotide (SOM230) Prevents Sulfonylurea-induced Hypoglycemia in Rats
Publikationsverlauf
received 09. Juli 2014
first decision 23. Dezember 2014
accepted 07. Januar 2015
Publikationsdatum:
06. Februar 2015 (online)
![](https://www.thieme-connect.de/media/eced/201503/lookinside/thumbnails/10.1055-s-0034-1398552-1.jpg)
Abstract
Persistent hypoglycemia is a serious condition that is frequently reported in patients undergoing sulfonylurea treatment, often necessitating hospitalization in the event of overdose. Somatostatin is a regulatory hormone with a broad range of physiological actions that include the inhibition of insulin and glucagon secretion, predominantly via activation of the somatostatin receptor subtypes sstr5 and sstr2, respectively. Previous studies have demonstrated that octreotide, a potent somatostatin analogue with high affinity for sstr2 and moderate affinity for sstr5, significantly increases serum glucose levels and prevents recurrence of hypoglycemic episodes in patients with sulfonylurea-induced hypoglycemia. Pasireotide (SOM230) is a multireceptor-targeted somatostatin analogue with a 39-, 30- and 5-fold higher binding affinity for sstr5, sstr1 and sstr3, respectively, and a slightly lower (0.4-fold) affinity for sstr2 compared with octreotide. This study evaluated the effects of pasireotide and octreotide in rats with glyburide-induced hypoglycemia. In fasted rats, pasireotide (10 and 30 µg/kg) prevented glyburide-induced hypoglycemia in a dose-dependent manner for up to 6 h. Qualitatively similar results were observed in non-fasted rats. However, the antihypoglycemic effect of pasireotide was stronger in non-fasted rats, resulting in transient hyperglycemia. In contrast to pasireotide, octreotide 10 µg/kg did not prevent glyburide-induced hypoglycemia in fasted and non-fasted rats, while octreotide 30 µg/kg resulted in small but significant increases in blood glucose at 3 h post-dose only. These findings suggest that pasireotide could have a more potent effect than octreotide in the management of patients with severe hypoglycemia caused by hyperinsulinemia.
-
References
- 1 Dougherty PP, Klein-Schwartz W. Octreotide’s role in the management of sulfonylurea-induced hypoglycemia. J Med Toxicol 2010; 6: 199-206
- 2 Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005; 172: 213-226
- 3 Fasano CJ, Rowden AK, O’Malley GF et al. Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series. Am J Emerg Med 2010; 28: 952-955
- 4 Bronstein AC, Spyker DA, Cantilena Jr LR et al. 2010; Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49: 910-941
- 5 Van Op den Bosch J, Adriaensen D, Van Nassauw L et al. The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: A review. Regul Pept 2009; 156: 1-8
- 6 Hauge-Evans AC, King AJ, Carmignac D et al. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 2009; 58: 403-411
- 7 Zambre Y, Ling Z, Chen MC et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 1999; 57: 1159-1164
- 8 Rossowski WJ, Coy DH. Potent inhibitory effects of a type four receptor-selective somatostatin analog on rat insulin release. Biochem Biophys Res Commun 1993; 197: 366-371
- 9 Singh V, Brendel MD, Zacharias S et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007; 92: 673-680
- 10 Rossowski WJ, Coy DH. Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochem Biophys Res Commun 1994; 205: 341-346
- 11 Fasano CJ, O’Malley G, Dominici P et al. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51: 400-406
- 12 Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004; 80 (Suppl. 01) 47-50
- 13 Schmid HA, Brueggen J. Effects of somatostatin analogues on glucose homeostasis in rats. J Endocrinol 2012; 212: 49-60
- 14 Clark MA, Humphrey SJ, Smith MP et al. Unique natriuretic properties of the ATP-sensitive K(+)-channel blocker glyburide in conscious rats. J Pharmacol Exp Ther 1993; 265: 933-937
- 15 Mitra SW, Mezey E, Hunyady B et al. Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 1999; 140: 3790-3796
- 16 Rowden AK, Fasano CJ. Emergency management of oral hypoglycemic drug toxicity. Emerg Med Clin North Am 2007; 25: 347-356
- 17 Dougherty PP, Klein-Schwartz W. Octreotide’s role in the management of sulfonylurea-induced hypoglycemia. J Med Toxicol 2010; 6: 199-206
- 18 Henry RR, Ciaraldi TP, Armstrong D et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013; 98: 3446-3453
- 19 Boscaro M, Ludlam WH, Atkinson B et al. Treatment of pituitary dependent Cushing’s disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009; 94: 115-122